Ready to Improve Your Biomarker Intelligence?

TALK TO A BIOMARKER STRATEGIST

FDA Approves Blinatumomab for Acute Lymphoblastic Leukemia

by

Good news regarding a new personalized cancer therapy that has just been approved after showing very strong efficacy during clinical trials.

Blinatumomab is a novel CD19-directed immunotherapy from Amgen that is a great example of personalized medicine in action.

It is a treatment for leukemia patients who are negative for the Philadelphia chromosome biomarker, and utilizes a first-of-its-kind approach to stimulating the body’s own ability to destroy cancer cells.

Read the press release here.